Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Pharmiweb.com RSS Feed PharmiWeb Candidate Blog

Pharmiweb.com RSS Feed PharmiWeb Client Blog

Advertising

Features

Features
PharmiWeb Solutions is expanding

28 Nov 07

Are you keen to join a young, entrepreneurial, fast growth organisation? We'd like to hear from you.
Colin Williams

Pharma ROI – RIP or SOP?

27 Nov 07

PharmiWeb Solutions’ Managing Director Paul Hartigan was a speaker at the annual conference of the Pharmaceutical Marketing Society in London yesterday, November 26th, hosted by the Royal College of Nurses. He reviews his thoughts on the day here.
Editor

Franchising & Novou-Consumerism in Middle East

25 Sep 07

Two things; firstly among all of the great business concepts of the last few decades the franchise model has always surfaced to the very top. Secondly, over the next decade the introduction of hundreds of fresh, locally nurtured franchise concepts emerging within Dubai and the Gulf States will set the stage for a great revolution of nouvo-consumerism. So what are the four key factors driving this movement?
Naseem Javed

PharmiWeb Solutions shortlisted for the Best Online Publisher awards

06 Sep 07

Healthcare specialist online publisher and e-business services provider PharmiWeb Solutions has been shortlisted for the Best Online Publisher awards by the UK Association of Online Publishers (AOP). Paul Hartigan, PharmiWeb CEO, commented on the news, which was announced this week, “We’re delighted to be shortlisted for such a prestigious award.
Colin Williams

BIPOLAR DISORDER: a new holistic approach

30 Jul 07

BIPOLAR DISORDER: a new holistic approach to controlling mood disturbance from multiple aspects could revolutionise patients’ prospects
Olwen Glynn Owen

Wyeth Reports Earnings Results for the 2007 Second Quarter and First Half

25 Jul 07

Madison, N.J., July 19, 2007 - Wyeth (NYSE: WYE) today reported results for the 2007 second quarter and first half ending June 30, 2007. Worldwide net revenue increased 10% to $5.6 billion for the 2007 second quarter and 10% to $11.0 billion for the 2007 first half. Excluding the favorable impact of foreign exchange, worldwide net revenue increased 7% for the 2007 second quarter and 8% for the 2007 first half.
Douglas Petkus

Market Leading Pharmaceutical Recruitment Consultancy Barrington James Limited is happy to announce the appointment of Tony Kelleher as its Sales Manager

02 Jul 07

Barrington James Limited currently places candidates extensively throughout the UK and Europe in many areas such as Clinical Research, Regulatory Affairs, Medical Affairs, Data Management and Business Development. Working with key Barrington James Team Leaders such as Paul Duffy, Tony Kelleher will be charged with growing the team to assist with their Client’s needs throughout Europe. Dan Barrington, Director, said “…we are delighted Tony agreed to join Barrington James Limited, he brings
Dan Barrington

Erbitux moves to front-line in attack against both metastatic head and neck and colorectal cancers

11 Jun 07

The anti-EGFR targeting cancer therapy Erbitux (cetuximab), has been approved in Europe for the treatment of locally advanced head and neck cancer in conjunction with radiotherapy and as a third-line treatment in combination with irinotecan-based chemotherapy for patients with metastatic colorectal cancer. New data from the phase III EXTREME and CRYSTAL trials, presented at the American Society of Clinical Oncology’s annual meeting, show cetuximab added to chemotherapy is also an effective first
Olwen Glynn Owen

Sponsor a CEO

11 Jun 07

Those of you who know our CEO Paul Hartigan will realise that he is a keen cyclist (we have to repeatedly ask him not to turn up to customer meetings in some of his garishly coloured Lycra).
Editor

CRYSTAL trial reveals benefits of first-line cetuximab in mCRC

08 Jun 07

Results of the CRYSTAL trial investigating first-line cetuximab therapy in addition to irinotecan-based therapy in metastatic colorectal cancer (mCRC) were presented by the study’s lead investigator, Professor Eric Van Cutsem of University Hospital, Gasthuisberg, Leuven, Belgium.
Olwen Glynn Owen

Advertising
Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.